Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
Completed
Takeda
2011-11-28
The purpose of this survey is to examine the safety and efficacy of long-term use of
alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus
determined as warranting combination therapy with alogliptin benzoate and pioglitazone
hydrochloride
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
Recruiting
Celltrion Pharm, Inc.
Phase 4
2020-02-11
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is
non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin
(HbA1c) change from baseline at Week 52.
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
Recruiting
Takeda
Phase 4
2020-02-11
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is
non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin
(HbA1c) change from baseline at Week 52.
To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes
Recruiting
Yonsei University
Phase 4
2020-05-29
This study was designed to evaluate the effect of Nesinaact on non-alcoholic steatohepatitis
through magnetic resonance imaging (MRI)-based proton density-fat fraction (MRI-PDFF) and
liver fibroscan in patients with type 2 diabetes. This is a prospective, open-label,
single-arm, single-center clinical Study. After 24 weeks of Nesinaact 25/15 (Alogliptin
benzoate 25mg, pioglitazone hydrochloride 15mg) treatment, the improvement of parameters
estimated by MRI and liver fibroscan will be estimated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
